Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

[Atypical lobular hyperplasia (ALH)].

Kasami M, Oishi T.

Nihon Rinsho. 2012 Sep;70 Suppl 7:391-6. Japanese. No abstract available.

PMID:
23350428
3.

[Atypical ductal and lobular hyperplasia of the breast].

Bricou A, Delpech Y, Barranger E.

Gynecol Obstet Fertil. 2009 Oct;37(10):814-9. doi: 10.1016/j.gyobfe.2009.06.006. Epub 2009 Sep 17. Review. French.

PMID:
19766043
4.

Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology.

Lishman SC, Lakhani SR.

Histopathology. 1999 Sep;35(3):195-200. Review.

PMID:
10469210
5.

Evolving concepts in the management of lobular neoplasia.

Anderson BO, Calhoun KE, Rosen EL.

J Natl Compr Canc Netw. 2006 May;4(5):511-22. Review.

PMID:
16687097
6.

Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy.

McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, Dupont WD, Page DL.

Cancer. 2006 Sep 15;107(6):1227-33.

7.

Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification.

Zhao C, Desouki MM, Florea A, Mohammed K, Li X, Dabbs D.

Am J Clin Pathol. 2012 Jul;138(1):72-8. doi: 10.1309/AJCPYG48TUTFIBMR.

PMID:
22706860
8.

Surgical outcome of biopsy-proven lobular neoplasia: is there any difference between lobular carcinoma in situ and atypical lobular hyperplasia?

Ibrahim N, Bessissow A, Lalonde L, Mesurolle B, Trop I, Lisbona A, El-Khoury M.

AJR Am J Roentgenol. 2012 Feb;198(2):288-91. doi: 10.2214/AJR.11.7212.

PMID:
22268170
9.

Fine-needle aspiration of mammary lobular carcinoma in situ and atypical lobular hyperplasia.

Salhany KE, Page DL.

Am J Clin Pathol. 1989 Jul;92(1):22-6.

PMID:
2750704
10.

The significance of atypical lobular hyperplasia at percutaneous breast biopsy.

Dmytrasz K, Tartter PI, Mizrachy H, Chinitz L, Rosenbaum Smith S, Estabrook A.

Breast J. 2003 Jan-Feb;9(1):10-2.

PMID:
12558664
11.
12.

Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.

Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.

Cancer. 2006 Jan 1;106(1):42-50.

13.

Clinicopathologic analysis of breast lesions associated with multiple papillomas.

Ali-Fehmi R, Carolin K, Wallis T, Visscher DW.

Hum Pathol. 2003 Mar;34(3):234-9.

PMID:
12673557
14.

The clinical significance of lobular neoplasia on breast core biopsy.

Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ.

Am J Surg Pathol. 2007 May;31(5):717-23.

PMID:
17460455
15.

Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast--a review.

Hussain M, Cunnick GH.

Eur J Surg Oncol. 2011 Apr;37(4):279-89. doi: 10.1016/j.ejso.2011.01.009. Review.

PMID:
21306860
16.
17.

In situ and invasive lobular neoplasia of the breast.

Hanby AM, Hughes TA.

Histopathology. 2008 Jan;52(1):58-66. doi: 10.1111/j.1365-2559.2007.02891.x. Review.

PMID:
18171417
18.
19.

Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy.

Shin SJ, Rosen PP.

Arch Pathol Lab Med. 2002 Jun;126(6):697-701.

PMID:
12033958
20.

Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types.

Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA.

Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301.

Supplemental Content

Support Center